Page 44 - 2021_07-Haematologica-web

G.E. Linder and S.T. Chou
ing pre-operative transfusion in sickle cell anaemia. Bahrain Med Bull. 2006;28(4):164- 167.
38. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggres- sive transfusion regimens in the periopera- tive management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995;333(4):206-213.
39. Lagresle-Peyrou C, Lefrère F, Magrin E, et al. Plerixafor enables safe, rapid, efficient mobi- lization of hematopoietic stem cells in sickle cell disease patients after exchange transfu- sion. Haematologica. 2018;103(5):778-786.
40. Karafin MS, Westlake M, Hauser RG, et al. Risk factors for red blood cell alloimmuniza- tion in the Recipient Epidemiology and Donor Evaluation Study (REDS-III) data- base. Br J Haematol. 2018;181(5):672-681.
41. Fasano RM, Meyer EK, Branscomb J, White MS, Gibson RW, Eckman JR. Impact of red blood cell antigen matching on alloimmu- nization and transfusion complications in patients with sickle cell disease: a systematic review. Transfus Med Rev. 2019;33(1):12-23.
42. Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol. 2012;159(4):394-404.
43. Vichinsky EP, Earles A, Johnson RA, Hoag MS, Williams A, Lubin B. Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood. N Engl J Med. 1990;322(23):1617-1621.
44. Rosse WF, Gallagher D, Kinney TR, et al. Transfusion and alloimmunization in sickle cell disease. The Cooperative Study of Sickle Cell Disease. Blood. 1990;76(7):1431-1437.
45. Reid ME, Lomas-Francis C. The Blood Group Antigen FactsBook. 2004. Academic Press.
46. Olujohungbe A, Hambleton I, Stephens L, Serjeant B, Serjeant G. Red cell antibodies in patients with homozygous sickle cell dis- ease: a comparison of patients in Jamaica and the United Kingdom. Br J Haematol. 2001;113(3):661-665.
47. Natukunda B, Schonewille H, Ndugwa C, Brand A. Red blood cell alloimmunization in sickle cell disease patients in Uganda. Transfusion. 2010;50(1):20-25.
48. Boateng LA, Campbell AD, Davenport RD, et al. Red blood cell alloimmunization and minor red blood cell antigen phenotypes in transfused Ghanaian patients with sickle cell disease. Transfusion. 2019;59(6):2016-2022.
49. Chou ST, Jackson T, Vege S, Smith-Whitley K, Friedman DF, Westhoff CM. High preva- lence of red blood cell alloimmunization in sickle cell disease despite transfusion from Rh-matched minority donors. Blood. 2013;122(6):1062-1071.
50. Sesok-Pizzini DA, Friedman DF, Smith- Whitley K, Nance SJ. Transfusion support of patients with sickle cell disease at the Children's Hospital of Philadelphia. Immunohematology. 2006;22(3):121-125.
51. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014;312 (10):1033-1048.
52. Ambruso DR, Githens JH, Alcorn R, et al. Experience with donors matched for minor blood group antigens in patients with sickle cell anemia who are receiving chronic trans- fusion therapy. Transfusion. 1987;27(1):94- 98.
53. Lasalle-Williams M, Nuss R, Le T, et al. Extended red blood cell antigen matching
for transfusions in sickle cell disease: a review of a 14-year experience from a single center (CME). Transfusion. 2011;51(8):1732- 1739.
54. Chou ST, Evans P, Vege S, et al. RH genotype matching for transfusion support in sickle cell disease. Blood. 2018;132(11):1198-1207.
55. Veldhuisen B, van der Schoot CE, de Haas M. Blood group genotyping: from patient to high-throughput donor screening. Vox Sang. 2009;97(3):198-206.
56.Casas J, Friedman DF, Jackson T, Vege S, Westhoff CM, Chou ST. Changing practice: red blood cell typing by molecular methods for patients with sickle cell disease. Transfusion. 2015;55(6 Pt 2):1388-1393.
57. Wilkinson K, Harris S, Gaur P, et al. Molecular blood typing augments serologic testing and allows for enhanced matching of red blood cells for transfusion in patients with sickle cell disease. Transfusion. 2012;52(2):381-388.
58. Ribeiro KR, Guarnieri MH, da Costa DC, Costa FF, Pellegrino J Jr, Castilho L. DNA array analysis for red blood cell antigens facilitates the transfusion support with anti- gen-matched blood in patients with sickle cell disease. Vox Sang. 2009;97(2):147-152.
59. Sippert E, Fujita CR, Machado D, et al. Variant RH alleles and Rh immunisation in patients with sickle cell disease. Blood Transfus. 2015;13(1):72-77.
60. Cohn CS, Delaney M, Johnson ST, Katz LM. Technical Manual, 20th edition. Bethesda, MD: AABB Press, 2020.
Chou ST, Flanagan JM, Vege S, et al. Whole- exome sequencing for RH genotyping and alloimmunization risk in children with sick- le cell anemia. Blood Adv. 2017;1(18):1414- 1422.
ease. Br J Haematol. 2015;168(2):291-300. 71. Vingert B, Tamagne M, Desmarets M, et al. Partial dysfunction of Treg activation in sick- le cell disease. Am J Hematol. 2014;89(3):
261-266.
72. Bao W, Zhong H, Manwani D, et al.
Regulatory B-cell compartment in trans- fused alloimmunized and non-alloimmu- nized patients with sickle cell disease. Am J Hematol. 2013;88(9):736-740.
73. Pal M, Bao W, Wang R, et al. Hemolysis inhibits humoral B cell responses and modu- lates alloimmunization risk in patients with sickle cell disease. Blood. 2021;137(2):269- 280.
74.Thein SL, Pirenne F, Fasano RM, et al. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica. 2020;105(3):539-544.
75. Harm SK, Yazer MH, Monis GF, Triulzi DJ, Aubuchon JP, Delaney M. A centralized recipient database enhances the serologic safety of RBC transfusions for patients with sickle cell disease. Am J Clin Pathol. 2014;141(2):256-261.
76. Habibi A, Mekontso-Dessap A, Guillaud C, et al. Delayed hemolytic transfusion reac- tion in adult sickle-cell disease: presenta- tions, outcomes, and treatments of 99 refer- ral center episodes. Am J Hematol. 2016;91 (10):989-994.
77. Chadebech P, Habibi A, Nzouakou R, et al. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death. Transfusion. 2009;49(9):1785- 1792.
78.Win N, Doughty H, Telfer P, Wild BJ, Pearson TC. Hyperhemolytic transfusion reaction in sickle cell disease. Transfusion. 2001;41(3):323-328.
79. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS. Phosphatidylserine externalization in sick- le red blood cells: associations with cell age, density, and hemoglobin F. Blood. 2003;102(1):365-370.
80.Narbey D, Habibi A, Chadebech P, et al. Incidence and predictive score for delayed hemolytic transfusion reaction in adult patients with sickle cell disease. Am J Hematol. 2017;92(12):1340-1348.
81. Vidler JB, Gardner K, Amenyah K, Mijovic A, Thein SL. Delayed haemolytic transfu- sion reaction in adults with sickle cell dis- ease: a 5-year experience. Br J Haematol. 2015;169(5):746-753.
82. de Montalembert M, Dumont MD, Heilbronner C, et al. Delayed hemolytic transfusion reaction in children with sickle cell disease. Haematologica. 2011;96(6):801- 807.
83. Pirenne F, Yazdanbakhsh K. How I safely transfuse patients with sickle-cell disease and manage delayed hemolytic transfusion reactions. Blood. 2018;131(25):2773-2781.
84. Merle NS, Grunenwald A, Rajaratnam H, et al. Intravascular hemolysis activates comple- ment via cell-free heme and heme-loaded microvesicles. JCI Insight. 2018;3(12): e96910.
85. Chonat S, Quarmyne MO, Bennett CM, et al. Contribution of alternative complement pathway to delayed hemolytic transfusion reaction in sickle cell disease. Haematologica. 2018;103(10):e483-e485.
86. Floch A, Morel A, Zanchetta-Balint F, et al. Anti-C5 antibody treatment for delayed hemolytic transfusion reactions in sickle cell disease. Haematologica. 2020;105(11):2694- 2697.
61.
62.
63.
64.
65.
66.
Srivastava K, Polin H, Sheldon SL, et al. The DAU cluster: a comparative analysis of 18 RHD alleles, some forming partial D anti- gens. Transfusion. 2016;56(10):2520-2531. Tournamille C, Meunier-Costes N, Costes B, et al. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization. Transfusion. 2010;50 (1):13-19.
Noizat-Pirenne F, Lee K, Pennec PY, et al. Rare RHCE phenotypes in black individuals of Afro-Caribbean origin: identification and transfusion safety. Blood. 2002;100(12): 4223-4231.
Tatari-Calderone Z, Gordish-Dressman H, Fasano R, et al. Protective effect of HLA- DQB1 alleles against alloimmunization in patients with sickle cell disease. Hum Immunol. 2016;77(1):35-40.
Hoppe C, Klitz W, Vichinsky E, Styles L. HLA type and risk of alloimmunization in sickle cell disease. Am J Hematol. 2009;84(7): 462-464.
67. Meinderts SM, Gerritsma JJ, Sins JWR, et al. Identification of genetic biomarkers for alloimmunization in sickle cell disease. Br J Haematol. 2019;186(6):887-899.
68. Williams LM, Qi Z, Batai K, et al. A locus on chromosome 5 shows African ancestry-lim- ited association with alloimmunization in sickle cell disease. Blood Adv. 2018;2(24): 3637-3647.
69. Jison ML, Munson PJ, Barb JJ, et al. Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. Blood. 2004;104(1):270-280.
70. Fasano RM, Booth GS, Miles M, et al. Red blood cell alloimmunization is influenced by recipient inflammatory state at time of transfusion in patients with sickle cell dis-
1814
haematologica | 2021; 106(7)